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Abstract 
Purpose: Abiraterone may suppress androgens that stimulate breast cancer growth. We 
conducted a biomarker analysis of circulating tumor cells (CTCs), formalin-fixed paraffin-
embedded tissues (FFPETs), and serum samples from postmenopausal estrogen receptor 
(ER)+ breast cancer patients to identify subgroups with differential abiraterone sensitivity. 
Methods: Patients (randomized 1:1:1) were treated with 1,000 mg/d abiraterone acetate + 5 
mg/d prednisone (AA), AA + 25 mg/d exemestane (AAE), or exemestane. The biomarker 
population included treated patients (n = 293). The CTC population included patients with ≥ 3 
baseline CTCs (n = 104). Biomarker (e.g., androgen receptor [AR], ER, Ki-67, CYP17) 
expression was evaluated. Cox regression stratified by prior therapies in the metastatic setting 
(0/1 vs. 2) and setting of letrozole/anastrozole (adjuvant vs. metastatic) was used to assess 
biomarker associations with progression-free survival (PFS).  
Results: Serum testosterone and estrogen levels were lowered and progesterone increased 
with AA. Baseline AR or ER expression was not associated with PFS in CTCs or FFPETs for 
AAE versus exemestane but dual positivity of AR and ER expression was associated with 
improved PFS (HR 0.41 [95% confidence interval (CI), 0.16–1.07], P = 0.070). For AR 
expression in FFPETs obtained < 1 year prior to first dose (n = 67), a trend for improved PFS 
was noted for AAE versus exemestane (HR 0.56 [95% CI, 0.24–1.33], P = 0.19).  
Conclusion: An AA pharmacodynamic effect was shown by decreased serum androgen and 
estrogen levels and increased progesterone. AR and ER dual expression in CTCs and newly 
obtained FFPETs may predict AA sensitivity.  
ClinicalTrials.gov: NCT01381874 
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Translational Relevance 
A subset of nonsteroidal aromatase inhibitor-resistant, estrogen receptor-positive breast 
cancers may be sensitive to antiandrogen drugs and thus may derive clinical benefit from the 
androgen biosynthesis inhibitor abiraterone acetate (AA). A biomarker analysis can be useful to 
identify predictive biomarkers for AA sensitivity or resistance. The effect of AA administration on 
serum testosterone has been well characterized but not the effect on a panel of other serum 
endocrine biomarkers. In our biomarker analysis, a positive pharmacodynamic effect of AA was 
shown by the decrease in serum estrogens and androgen and potentially by the increase in 
progesterone in most AA-treated patients. Despite association trends of certain biomarkers with 
progression-free survival (PFS), none of the biomarkers, either as single markers or in 
combination, could identify a subpopulation of patients with significant added clinical benefit 
from AA. Importantly, no association between the elevated serum progesterone induced by AA 
administration and PFS was observed. 
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Introduction 
Elucidating the role of androgens in estrogen receptor (ER)+ metastatic breast cancer has 
recently been a subject of interest as androgenic signaling is predicted to be a potential 
mechanism of therapeutic resistance to antiestrogenic therapy (1-3). Androgens are the most 
prominent sex hormone in women after menopause, which may allow for androgen 
aromatization to estradiol and breast cancer progression through androgen receptor (AR) 
stimulation in a low-estrogenic environment (4). More than 60% of breast cancers express AR 
and androgen-regulated proteins, indicating potential androgen responsiveness (4, 5). 
Furthermore, exogenous AR overexpression renders tamoxifen-sensitive ER+ breast cancer cell 
lines resistant to tamoxifen, providing additional evidence for AR as a target for therapeutic 
augmentation of combination endocrine therapies in breast cancer (6). 
 
As such, certain subsets of breast cancers may then be sensitive to antiandrogen strategies and 
thus may derive clinical benefit from the androgen biosynthesis inhibitor abiraterone acetate 
(AA), which has proved to be effective in hormone-driven prostate cancer (7, 8). In an early-
phase, nonrandomized trial of postmenopausal ER+ patients with advanced breast cancer 
progressing on ≥ two lines of endocrine therapy, AA treatment was associated with a reduction 
in serum androgens and estrogens (9); one patient had a confirmed partial response lasting 
13.8 months, and 22% of patients had clinical benefit for ≥ 24 weeks, providing preliminary 
evidence of efficacy of AA in advanced breast cancer (9). However, in the randomized phase II 
study BCA2001 of ER+ HER2– postmenopausal breast cancer patients who had progressed on 
nonsteroidal aromatase inhibitors (NSAIs), no improvement in the primary endpoint of 
progression-free survival (PFS) was observed with the addition of AA to exemestane compared 
with exemestane alone (4.5 vs. 3.7 months, hazard ratio [HR] [95% confidence interval (CI)] = 
0.96 [0.70–1.32]; P = 0.79) (10). As androgen blockage remains a potential therapeutic strategy 
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for a clinically defined subset of breast cancer patients, further understanding of the 
pathogenesis of breast cancer and mechanism of action of AA in breast cancer patients would 
provide the framework for individualization of this drug therapy. 
 
We hypothesized that breast cancer tumors with active AR signaling or residual ER activity after 
progression on an aromatase inhibitor may derive clinical benefit from AA. We therefore 
conducted a biomarker analysis of study BCA2001 to analyze serum steroid concentrations for 
changes from baseline and to potentially identify subgroups with AA sensitivity or resistance 
using tumor biomarkers in archival formalin-fixed paraffin-embedded tissues (FFPETs) and 
circulating tumor cell (CTC) samples. We also investigated the congruency of biomarkers in 
these two sample types.  
 
Patients and Methods 
Study design and treatments 
BCA2001 is a randomized, open-label, multicenter phase II study of 1,000 mg AA plus 5 mg 
prednisone daily (hereafter referred to as AA) versus AA plus prednisone with 25 mg 
exemestane (AAE) daily versus the control arm (25 mg exemestane alone daily [E]) in patients 
with postmenopausal ER+ HER2– breast cancer after receiving NSAIs (10). Patients could have 
had no more than two prior systemic treatments in the metastatic setting, of which one could be 
chemotherapy, and an Eastern Cooperative Oncology Group performance status (ECOG PS) 
score of ≤ 1. Patients were stratified by the number of prior therapies in the metastatic setting (0 
or 1 vs. 2) and the setting of prior letrozole or anastrozole treatment (adjuvant vs. metastatic).  
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The review boards at all participating institutions approved the study, which was conducted 
according to the Declaration of Helsinki; all patients provided written, informed consent to 
participate in the study. 
 
Biomarker analysis 
Several biomarkers associated with the mechanism of action of the study drugs, or with the 
development and progression of breast cancer, were evaluated from archival FFPETs, CTCs, 
and serum samples (Supplementary Table S1).  
 
Immunohistochemistry and FISH analysis of archival FFPETs 
Immunohistochemistry (IHC) and FISH analysis of archival FFPETs were conducted at 
Phenopath Labs (Seattle, Washington). IHC analysis was used to assess the baseline 
expression of ER (Thermofisher #RM-9101-S; SP1 clone), progesterone receptor (PR; Dako 
#M3569; PgR636 clone), HER2 (Thermo-Fisher #RM-9103-S, SP3 clone), cytochrome P450 
17A1 (CYP17A1; Abcam#Ab80206), aromatase/cytochrome P450 19A1 (CYP19A1; Novus 
Biological #AP00001PU-N), Ki-67 (Dako, #M7240; MIB-1 clone), and AR (Dako, #M3562, Clone 
AR441), in FFPETs. The percentage of positively staining cells, intensity of staining (weak, 
moderate, strong), and presence of positive internal controls were evaluated. ER and PR 
positivity were accessed by scoring according to the American Society of Clinical Oncology 
College of American Pathologists (ASCO/CAP) guidelines (11). Expression of ER and PR at 
any intensity greater than 1% of tumor cells was considered positive. Expression of HER2 was 
accessed with a modified ASCO/CAP guideline (12). For HER2, CYP17, and CYP19, the 
cutpoint for positive expression was also 1% of tumor cells. To determine Ki-67 positivity, 
nuclear staining was scored as percentage of cells positive relative to nonreactive cells within 
the target. Expression of Ki-67 and AR at any intensity greater than 10% of tumor cells was 
considered positive. 
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IHC and FISH analysis of CTCs 
Blood samples (40 mL) were taken on day 1 of cycles 1 and 2 and at the end of treatment 
(EOT) or disease progression, and shipped to the Janssen Diagnostics CRS lab for CTC 
enumeration (CellSearch®; Janssen Diagnostics, LLC, Raritan, NJ) and molecular 
characterization as previous described (13, 14). A three-CTC threshold is used for CTC 
molecular marker evaluations, whereas a five-CTC threshold separates favorable and 
unfavorable prognosis. Only samples with three or more evaluable CTCs were included to 
ensure confidence of positive versus negative biomarker determinations. Biomarkers tested in 
CTCs included expression of AR (Cell Signaling Technology #8428, D6F11 clone), ER (Janssen 
Diagnostics ER-119.3), and Ki-67 (BD Pharmingen #556027, clone B56) by 
immunofluorescence. For ER and Ki-67 expression analysis, the percentage of positive cells 
was determined by nuclear fluorescence in the phycoerythrin channel, with > 80% positive 
MCF-7 cells spiked into normal donor blood as a positive control. For AR expression analysis, 
LNCaP cells were spiked into normal donor blood as a positive control and PC-3 cells as a 
negative control. The cutpoints for positive expression of ER, Ki-67, and AR were the same as 
noted above.  
 
A four-color FISH assay was developed for use on enriched CTC to simultaneously detect 
amplification of HER2 and AR genes as well as aneusomy of chromosomes X and 17. The 
assay uses control probes on the centromere of chromosome 17 (Kreatech SE17, Leica 
Biosystems) and the X chromosome (Kreatech SE-X, Leica Biosystems) to determine the 
overall ploidy level of the cell assessed. The Clone IDs for bacterial artificial chromosomes 
(BACs) utilized as probes to evaluate HER2 were RP11-62N23, RP11-94L15, and RP11-
387H17. BAC clones evaluated for AR were RP11-383C12, RP11-479J1, and RP11-963N10. 
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Samples were considered positive for FISH, positive for HER2 and AR gene amplification if ≥ 
three CTCs were found to contain five or more copies of the target gene. 
 
Evaluation of serum hormone concentrations 
Blood samples (15 mL) for assessment of endocrine biomarkers were taken day 1 of cycles 1 to 
3 and every three cycles thereafter (e.g., day 1 cycle 6; day 1 cycle 9), and at EOT or disease 
progression. Analysis of androgen and estrogen concentrations was conducted according to 
standard operating procedures (Covance Central Laboratory Services, Indianapolis, Indiana; 
and Geneva, Switzerland). Samples were analyzed for testosterone, estradiol, and estrone by 
liquid chromatography–mass spectrometry using an ABI Sciex QTRAP® 5500 system (Applied 
Biosystems/MDS Analytical Technologies, Foster City, California). Progesterone serum 
concentrations were determined using the Beckman Coulter Access Progesterone assay 
(Beckman Coulter Inc., Brea, California) and the Dxi 800 instrument. Progesterone 
concentrations were only determined for a subset of patients, because the serum progesterone 
analysis was added after enrollment was initiated. 
 
Statistical analysis 
Baseline demographics and disease characteristics were compared in the biomarker or CTC 
populations versus the intent-to-treat (ITT) population using ANOVA and chi-squared tests. 
Biomarkers were summarized in each of the three arms or combinations of the three arms by 
calculating the mean, standard deviation, median, range, and number of samples with 
expression for continuous variables, and the frequency of expression of categorical biomarkers 
(N and %) for categorical variables.  
 
For categorical variables, statistical comparisons were performed for treatment effect (AA vs. E, 
AAE vs. E, or AA and AAE vs. E) in biomarker positive/negative subgroups or for biomarker 
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effect (biomarker positive vs. negative) in treatment arms and overall population to identify 
patient subpopulations with better PFS. Composite biomarkers were generated by combining 
levels of biomarker pairs. For this composite biomarker, each individual biomarker was 
dichotomized to define biomarker positive and negative patient subpopulations using biomarker-
specific thresholds (e.g., AR 10%, ER 1%) or medians for endocrine biomarkers. The composite 
biomarker was defined by evaluating individual biomarkers concurrently, resulting in four 
subpopulations (i.e., AR+ and ER+, AR+ and ER–, AR– and ER+, AR– and ER–). Association 
between biomarker expression and time to event was represented by reporting the P value and 
hazard ratio with 95% CI and the median time to event with 95% CI from Kaplan-Meier analysis. 
A Cox proportional-hazards regression analysis of PFS was performed to evaluate the 
treatment effect (AA vs. E, AAE vs. E) in biomarker-positive and -negative subgroups, stratified 
according to number of prior therapies in the metastatic setting (0 or 1 vs. 2), and setting of prior 
letrozole or anastrozole treatment (adjuvant vs. metastatic). 
 
For serum endocrine markers, treatment effects were summarized by the mean, standard 
deviation, median, and range of expression levels, along with the change from baseline and 
percentage change from baseline. Longitudinal analysis was used to evaluate the effect of 
treatment on serum endocrine marker levels versus baseline within treatment arms. The change 
in serum endocrine marker levels was evaluated using a linear mixed-effects model with fixed 
effects for visit, treatment and the visit treatment interaction, and a random effect for patients. 
For CTC biomarkers, treatment effects were summarized by the count or average of total CTCs, 
count and percentage of biomarker-positive CTCs, change of total CTCs and biomarker-positive 
CTCs from baseline, and change in percentage of biomarker-positive CTCs.  
 
CTC conversion rates were enumerated by tabulating the number of patients in each treatment 
arm with ≥ five CTCs at baseline and < five CTCs at cycle 2 or EOT instead of the ≥ three CTCs 
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cutoff used to select patients for CTC molecular analysis. Additionally, the CTC conversion rates 
at cycle 2 and EOT were compared across treatment arms in biomarker (CTC or IHC AR 
expression) -positive versus -negative populations. Fisher’s exact test was used to test the 
associations between treatment arms and CTC conversion rate. Expression using IHC and CTC 
biomarkers at baseline was compared.  
 
Results 
Patient demographics 
Two hundred ninety-seven patients were enrolled in the BCA2001 trial starting in August 2011 
and were randomly assigned 1:1:1 to the E (n = 102), AA (n = 89), or AAE (n = 106) treatment 
arms (Fig. 1). The primary PFS results have been presented previously (15). Of the 293 patients 
(E, n = 102; AA, n = 87; AAE, n = 104) who received treatment and comprised the biomarker 
population, 104 (E, n = 37; AA, n = 31; AAE, n = 36) were evaluable at baseline and were 
included in the CTC biomarker population. The remaining patients were deemed unevaluable 
and were excluded from the analysis due to inadequate levels of CTCs, provision of samples 
outside the required timeframe for CTC testing, unsatisfactory samples due to insufficient blood 
volume, or unreliable samples due to failure of baseline CTC testing.  
 
The CTC biomarker populations were comparable to the ITT population with regard to patient 
demographics and baseline disease characteristics (10). The median age was 62 (39–81) and 
63 (37–87) years in the CTC biomarker population and ITT population, respectively. Visceral 
metastatic disease was observed in 40% versus 46% of the patients. Altogether, 23% versus 
28% of patients had two prior treatments in the metastatic setting with 66% compared to 64% of 
patients receiving a prior NSAI in this setting.  
 
Biomarker analysis  
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A longitudinal analysis of endocrine serum markers compared within arms at several time points 
is presented in Fig. 2. As expected, serum testosterone was significantly decreased over time 
(P < 0.0001) in the AA and AAE treatment arms (–93.7% and –93.1% change, respectively) but 
not in the E arm (–15.6%; P = 0.29) by C2D1. AA-induced suppression of testosterone was 
persistent in both arms through EOT (–76.3% and –76.2%, respectively). Estradiol and estrone 
levels were decreased in these AA treatment arms. No statistically significant difference in the 
reduction of estradiol or estrone was observed between arms (data not shown).  
 
A significant increase in serum progesterone concentrations was noted in AA-treated patients 
(2666.4% and 1689.0% in AA and AAE arms, respectively; P < 0.0001) compared with E alone 
(–56.6%; P > 0.99) by C2D1 (Fig. 2). In a separate analysis, the AA-induced increase in 
progesterone was not associated with PFS based on stratified Cox proportional-hazards 
regression analysis (data not shown). Upon further analysis of median PFS in the patients with 
a decrease in progesterone at C2D1 versus all patients, there was no association with shorter 
PFS in patients with a decrease in progesterone (data not shown).  
 
Baseline FFPETs and CTCs were evaluated for AR and ER as single and combined biomarkers 
to assess the impact of AA on PFS for ER+ HER2– disease. There was a positive association 
with PFS for the combination of AR and ER expression in CTCs in favor of AAE versus E (HR = 
0.41 [95% CI, 0.16–1.07]; P = 0.070) (Supplementary Table S2). Evaluated as single 
biomarkers, a positive expression of AR (Fig. 3A and 3B) or ER in baseline CTCs or in the 
FFPETs was not associated with an improvement in PFS with AA or AAE versus E. No 
association between negative AR expression and improved PFS in the three arms was also 
noted (Supplementary Fig. S1A and S1B). Loss of ER or AR expression in CTCs was also not 
associated with a difference in PFS with AA or AAE versus E. For patients with FFPETs 
obtained < 1 year prior to first dose (n = 67) (Fig. 3C), positive AR expression was associated 
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with an improvement in PFS for AAE versus E (HR = 0.56 [95% CI, 0.24–1.33]; P = 0.19). 
Negative AR expression in these same recent FFPETs was not associated with an improvement 
in PFS for AAE versus E (Supplementary Fig. S1C). For completeness, we evaluated the 
sensitivity of the results to the threshold used to dichotomize low versus high expression. We 
found that the results were invariant to the specific threshold chosen (data not shown). 
 
Additional biomarkers were evaluated for a potential association with PFS (Supplementary 
Table S2). A longer median PFS was observed for positive Ki-67 expression in CTC samples 
(defined as ≥ 10% staining) in AAE-treated patients (3.7 months, HR = 0.26 [95% CI, 0.11–
0.64]; P = 0.003), and when AA and AAE arms were combined (3.5 months, HR = 0.36 [95% CI, 
0.17–0.76]; P = 0.007) compared with the E arm (1.9 months). Conversely, a statistically 
significant improvement in PFS with AAE was not noted for positive Ki-67 expression (≥ 10%) in 
FFPETs obtained at diagnosis. Patients with low serum estrone levels at baseline in the AAE 
and combined AA and AAE groups also showed an improvement in PFS over patients in the E 
arm (4.2 months, HR = 0.67 [95% CI, 0.43–1.04]; P = 0.07 vs. 3.7 months, HR = 0.71 [95% CI, 
0.48–1.05]; P = 0.09 vs. 1.9 months, respectively). No improvement in PFS was associated with 
expression of CYP17 or CYP19 in FFPETs. 
 
With regard to the post-baseline CTC analysis (Table 1), all patients’ CTCs were negative for 
ER amplification by FISH at baseline and post-baseline. There were significantly lower CTC 
counts in the AA arms compared with E alone at cycle 2 day 1 (P = 0.0075) but not at EOT 
(P = 0.95). No difference in CTC AR expression or CTC ER expression post-baseline was 
observed between treatment groups.  
 
Discordance in CTC and FFPET expression of biomarkers was observed. In total, 11 of 58 
(19%), 25 of 77 (33%), and 7 of 44 patients (16%) whose breast cancers were positive for 
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expression of AR, ER, and Ki-67, respectively, in FFPETs were negative on CTC analysis 
(Table 2). An observed discordance occurred in similar frequencies for all three of these 
biomarkers.  
 
Loss of ER expression may occur over time such that FFPETs initially characterized as ER+ 
may be ER– at the time of treatment for metastatic disease. Our analysis demonstrated that 
33% and 16% of initially positive breast cancer had lost ER or AR, respectively, in their CTCs. 
We evaluated whether loss of ER or AR is associated with worse outcomes by evaluating PFS 
differences between biomarker-positive and -negative patients for each of the AA treatment 
arms versus E. No significant differences in outcomes were observed (data not shown).  
 
Discussion 
This is the first report of a biomarker assessment of AA-treated postmenopausal ER+ advanced 
breast cancer patients based on serum endocrine analysis, FFPETs, and CTCs. The goal of this 
study was to assess baseline biomarkers that were highly associated with treatment response 
for stratification strategies and to track molecular and endocrine changes throughout the course 
of treatment. If a positive marker could be identified, uncertainty in predicting clinical benefit 
from current therapeutic options, which often leads to ineffective treatment of disease, can be 
avoided. Biomarker-driven therapeutic decision-making can potentially offer valuable 
information on surrogate markers for disease progression and treatment in the clinical setting. 
 
A positive pharmacodynamic effect of AA was shown by the decrease in serum androgen levels 
as well as estrogen levels (Fig. 2). Since CYP17 is upstream from aromatase in the steroid 
synthesis pathway, theoretically, AA should inhibit production of estrogens. Data from this study 
showed that AA decreased circulating estradiol and estrone to a level comparable to E alone.  
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A trend of sensitivity was observed in certain subsets of biomarkers analyzed in this study but 
the improvement in terms of longer PFS was generally not clinically significant. Baseline AR and 
ER expression in CTCs or FFPETs was not observed to be associated with improved PFS with 
AA or AAE versus E, though baseline AR and ER dual expression in CTCs may have an 
association with improved PFS (Supplementary Table S2).  
 
We hypothesized that loss of ER expression in CTCs might predict resistance to AA because of 
insensitivity of ER– tumors to hormonal therapy. However, even though loss of ER was 
observed in a subset of CTCs, it was not predictive of worse PFS with AA. Potential reasons for 
this outcome include discordance between diagnostic and CTC samples, or crosstalk between 
AR and ER signaling.  
 
Some limitations to analysis of CTC may have affected interpretations made from this study. 
One limitation is the small number of patients who have sufficient numbers of CTCs for analysis. 
In this study, only 39% (104/266) of the treated patients who provided CTCs had three or more 
CTCs at baseline for inclusion in the population for biomarker analysis. We found that there was 
81% concordance between AR positivity in FFPE versus CTC, whereas 32.5% of CTC samples 
lost ER expression. Loss of ER expression in CTCs can be attributed to a number of potential 
factors, including repopulation of tumor cells in response to various treatments after FFPETs 
were taken, intra- and inter-lesion heterogeneity of ER expression, lack of sufficient evaluable 
CTCs, and differences in IHC and CTC staining methods. Well-controlled future studies are 
needed to determine the exact cause of the discordance of ER status.  
 
Positive AR expression in FFPETs obtained < 1 year prior to the first dose was associated with 
improved PFS in the AAE arm versus E (Fig. 3C), while AR expression assessed in all the 
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archival FFPETs (some as old as 25.67 [0–25.67] years) was not. Samples collected more 
recently could have had a greater correlation of PFS with AA treatment due to antigen 
preservation, more recent samples being more representative of current tumor status, and/or 
differences in sample quality (signal may not be stable in older samples). In addition, a higher 
proportion of metastasis in recently collected samples compared with older samples (OR = 3.26, 
P = 0.005) could have affected these findings.  
 
The methods used in these analyses also did not allow for multiplex testing, which would have 
enabled multiple biomarkers to be measured simultaneously (16). This may affect data accuracy 
and appearance of discordance, as only a few individual molecular markers provide adequate 
sensitivity for CTC detection. Furthermore, multiple individual assays require sufficient CTC 
sample for each analysis, which limits the biomarker population to those patients who have 
higher levels of CTCs. Because of this, it is possible that patients were misclassified as 
biomarker-negative by CTC testing based on defined cutpoints because there were not enough 
CTCs detected and available for determination of status of individual CTCs, contributing to 
discordance.  
 
The lack of an observed positive association between AR expression and improved PFS with 
AA may be due to AA-induced progesterone production (Fig. 2). Progesterone potentially acts 
as an agonist that induces growth and survival of ER+ breast cancer. Importantly, in this 
evaluation of the association of baseline progesterone with PFS as continuous variable, patients 
with higher baseline progesterone concentrations had shorter PFS in all arms. The prognostic 
value of baseline progesterone, however, diminished after initiation of treatment in all arms. 
Evaluation of the association of elevated progesterone levels with PFS in samples on-treatment 
and post-treatment with AA was not feasible, because almost all patients treated with AA had 
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elevated serum progesterone levels. Progesterone levels were observed to be nominally 
lowered by 56.6% in the E arm at C2D1. This decrease of progesterone, however, was not 
statistically significant and was likely due to an outlier and not a real treatment effect.  
 
In conclusion, our analyses show that AA treatment decreased serum testosterone and 
estrogen levels but increased progesterone concentrations in ER+ HER2– NSAI-resistant 
metastatic breast cancer patients. Baseline AR and/or ER expression in CTCs or archival 
FFPETs was not associated with improved PFS for AA treatment arms versus E. However, an 
analysis of recent FFPETs, which may be more representative of the current metastatic disease 
biology, suggested that AR expression predicted for improved PFS with AA treatment, 
potentially due to the enrichment of AR in metastatic breast cancers that had been previously 
treated with a NSAI (6). Due to the small sample size, the hypotheses generated in these 
exploratory analyses need to be confirmed in further studies. However, due to a lack of 
significant improvement in clinical outcomes in the primary phase II trial (15), a phase III trial of 
the combination of AA and E in this breast cancer patient population was not pursued.  
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 Table 1. Post-baseline analysis of treatment effect on CTC markers 
Biomarker Visit Treatment N Mean Differential estimate (95% CI) P value 
CTC counts C1D1 E 36 45.89 – – 
AA 31 25.10 – – 
AAE 34 68.24 – – 
AA and AAE 65 47.66 – – 
C2D1 E 25 81.89 – – 
AA 28 27.25 –1.10 (–1.92 to –0.29) 0.0075 
AAE 31 24.35 –1.21 (–2.02 to –0.43) 0.0026 
AA and AAE 59 25.73 –1.16 (–1.89 to –0.48) 0.0012 
EOT E 20 48.68 – – 
AA 17 47.18 –0.03 (–0.92 to 0.88) 0.95 
AAE 20 77.66 0.47 (–0.39 to 1.33) 0.28 
AA and AAE 37 63.65 0.27 (–0.51 to 1.00) 0.48 
CTC AR C1D1 E 25 43.96 – – 
AA 25 45.20 – – 
AAE 30 35.70 – – 
AA and AAE 55 40.02 – – 
C2D1 E 19 51.74 – – 
AA 18 45.50 –6.24 (–24.14 to 11.67) 0.49 
AAE 25 41.48 –10.26 (–26.83 to 6.31) 0.22 
AA and AAE 43 43.16 –8.57 (–23.57 to 6.42) 0.26 
EOT E 14 41.07 – – 
AA 15 49.87 8.80 (–12.17 to 29.76) 0.41 
AAE 18 28.39 –12.68 (–32.78 to 7.42) 0.21 
AA and AAE 33 38.15 –2.92 (–20.91 to 15.07) 0.75 
CTC ER C1D1 E 25 27.84 – – 
AA 25 27.64 – – 
AAE 27 25.04 – – 
AA and AAE 52 26.29 –  
 22 
 
C2D1 E 12 19.75 – – 
AA 12 29.08 9.33 (–9.31 to 27.98) 0.32 
AAE 11 26.09 6.34 (–12.72 to 25.40) 0.51 
AA and AAE 23 27.65 7.90 (–8.36 to 24.16) 0.33 
EOT E 13 28.08 – – 
AA 13 37.54 9.46 (–13.70 to 32.62) 0.42 
AAE 18 28.17 0.09 (–21.40 to 21.58) 0.99 
AA and AAE 31 32.10 4.02 (–15.49 to 23.53) 0.68 
AR, androgen receptor; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; CI, confidence interval; CTC, circulating tumor cell; ER, estrogen 
receptor; EOT, end of treatment..
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Table 2. Discordance of CTC at baseline and FFPET at diagnosis 
 –CTC +CTC 
AR, n (%) – by IHC  4 (23.5) 13 (76.5) 
+ by IHC  11 (19.0) 47 (81.0) 
ER, n (%) – by IHC  – – 
+ by IHC  25 (32.5) 52 (67.5) 
Ki-67, n (%) – by IHC 7 (36.8) 12 (63.2) 
+ by IHC  7 (15.9) 37 (84.1) 
AR, androgen receptor; CTC, circulating tumor cell; ER, estrogen receptor; FFPET, formalin-
fixed paraffin-embedded tissue; IHC, immunohistochemistry.  
Cutpoints for positive expression: AR, 10%; ER, 1%; Ki-67, 10%. 
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Figure Legends 
Figure 1. CONSORT diagram. FFPETs were collected from all patients. E, exemestane; AA, 
abiraterone acetate; AAE, abiraerone acetate and exemestane; CTC, circulating tumor cell; ITT, 
intent-to-treat population. 
Figure 2. Longitudinal analysis of serum endocrine markers. (A) Testosterone. (B) 
Progesterone. (C) Estradiol. (D) Estrone. E, Exemestane; AA, abiraterone acetate; AAE, 
abiraterone acetate and exemestane; C1D1, cycle 1 day 1; C2D1, cycle 2 day 1; C3D1, cycle 3 
day 1; C6D1, cycle 6 day 1; C9D1, cycle 9 day 1; EOT, end of treatment. 
Figure 3. Comparison of associations of the positive baseline expression of androgen receptor 
(AR) (≥ 10%) with progression-free survival (PFS). (A) CTCs. (B) FFPETs by 
immunohistochemistry. (C) FFPETs collected < 1 year before first dose. Positive (≥ 10%). E, 
exemestane; AA, abiraterone acetate; AAE, abiraterone acetate and exemestane. 
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